SCHEMBL29968692

SCHEMBL29968692

NC(=O)c1ccc(N2CCN(C3c4ccccc4-c4ccccc43)CC2)c(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.52
MAPT P10636 8/20 0.48
KDM4E B2RXH2 4/20 0.48
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 1/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6687513 1.00 NPSR1 (0.52) NPSR1MAPTKDM4ELMNATP53
SCHEMBL6697423 0.85 NPSR1 (0.49) NPSR1MAPTKDM4ELMNATP53
SCHEMBL6797486 0.79 PARP14 (0.50) MAPTKDM4ELMNATP53L3MBTL1
SCHEMBL29968508 0.79 PARP14 (0.50) MAPTKDM4ELMNATP53L3MBTL1
SCHEMBL6684996 0.78 KDM4E (0.53) MAPTKDM4ELMNATP53GAA
SCHEMBL29968131 0.78 MAPT (0.51) NPSR1MAPTKDM4ELMNATP53
SCHEMBL29967752 0.78 KDM4E (0.53) MAPTKDM4ELMNATP53GAA
SCHEMBL6686127 0.78 MAPT (0.51) NPSR1MAPTKDM4ELMNATP53
SCHEMBL29968547 0.78 CCR3 (0.55) NPSR1MAPTKDM4ELMNATP53
SCHEMBL6799649 0.78 CCR3 (0.55) NPSR1MAPTKDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed
WO-2022192252-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2022-09-15 WO disclosed